As per the report titled ‘Global Active Pharmaceutical Ingredient (API) Market - Analysis By Drug Type (Generic, Innovative), Synthesis (Synthetic, Biotech), By Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global active pharmaceutical ingredient (API) market was valued USD 179.6 billion in 2020 and is anticipated to exhibit a healthy growth rate during the forecast period 2021-2026.

According to the findings of the research piece, booming aging population, technological advancements, increasing pharmaceutical manufacturing facilities, and continuous research & development activities by major companies are fostering global active pharmaceutical ingredient (API) market growth. Rising awareness and investments for new drugs development are further enhancing the industry outlook.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4489506/  

Elaborating on the COVID-19 impact, the pandemic has accelerated the industry expansion. The spike in death toll and rapid spread of the virus compelled various pharmaceutical and biopharmaceutical companies as well as startups to join forces and develop novel and effective drugs.

Based on drug type, the market is split into generic and innovative. In terms of synthesis, the industry is divided into biotech and synthetic. Moving on to the application spectrum, the segmentation comprises oncology, diabetes, cardiology, neurology, and others.

With respect to regional analysis, North America (U.S., Canada), Europe (U.K., Germany, Spain, France, Italy), and Asia Pacific (India, Japan, China) are the major geographies highlighted in global active pharmaceutical ingredient (API) industry report.

Asia Pacific market is anticipated to record substantial growth in the forthcoming years, mainly due to the presence of a huge population in India, China, and Japan which raises concerns regarding the growing prevalence of infectious diseases and chronic ailments in the region.

Speaking of the competitive landscape, biopharma companies are engaging in merger and acquisition deals to gain access to new technologies, expand market presence, and boost their capital for clinical trials and investments.

Boehringer Ingelheim, Bristol-Myers Squibb Co., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Merck KGaA, Eli Lily and Company, Novartis AG, AbbVie Inc., GlaxoSmithKline plc, and Pfizer are the major players in this business sphere.